One-day seminar on “The role of radiopharmaceuticals in the diagnosis and treatment of cancer” was held15th May 2022One-day seminar on “The role of radiopharmaceuticals in the diagnosis and…
One-day Seminar on The Role of Radiopharmaceuticals in the Diagnosis and Treatment of Cancer1st May 2022One-day Seminar on The Role of Radiopharmaceuticals in the Diagnosis and…
Unveiling of Pars Isotope’s latest products at the National Nuclear Technology Festival9th April 2022Unveiling of Pars Isotope’s latest products at the National Nuclear Technology…
The US Food and Drug Administration (FDA) Approves the Lu-177-PSMA Radiopharmaceutical28th March 2022The US Food and Drug Administration (FDA) Approves the Lu-177-PSMA Radiopharmaceutical…
The Head of the National Cancer Research Center visited Pars Isotope Co.22nd February 2022The Head of the National Cancer Research Center visited Pars Isotope…
Renewal of GMP certificate for production lines of Pars Isotope radiopharmaceutical products by IFDA13th February 2022Renewal of GMP certificate for production lines of Pars Isotope radiopharmaceutical…
The managers and news editors of IRIB made a visit to Pars Isotope Co.7th February 2022The managers and news editors of IRIB made a visit to…
Inauguration of Nuclear Medicine Department of Shahriar Specialized and Sub-Specialized Hospital6th February 2022Inauguration of Nuclear Medicine Department of Shahriar Specialized and Sub-Specialized Hospital…
Tc-99m-PSMA SPECT/CT Versus Ga-68-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer24th January 2022Tc-99m-PSMA SPECT/CT Versus Ga-68-PSMA PET/CT in the Evaluation of Metastatic Prostate…
Pars Isotope supports the fifth “Iranian Particle Accelerator Conference”28th December 2021Pars Isotope supports the fifth “Iranian Particle Accelerator Conference” Pars Isotope…